Optimizing NIA’s Eureka Prize Competition Topic

Submitted by

Caregivers need better transfer technology to make ADLs faster/safer for dementia patients

Suggestion category: Low-cost innovations to improve AD/ADRD care. Reason for entry: While the "ideas" site is for RFIs about the best ways to structure and frame the NIA's Eureka grant, this "application-like" idea attempts to motivate the NIA to focus the grant on gaps in assistive technology which make care giving challenging and unnecessarily costly. Drug therapies and more recently Internet-based information systems ...more »

Voting

5 votes

Optimizing NIA’s Eureka Prize Competition Topic

Submitted by (@dlorick)

Tag along Health Record (ipad, chromebook, like devices)

With most providers utilizing several different electronic health records and results from visits not share in the appropriate time frame. Or one shared patient portal related to his/her Alzheimer appointment. Recently has to take my family member to an urgent care facility as her PCP doesn't have weekend hours and we were at this appointment for five hours. My family member was severely dehydrated and required an ...more »

Voting

7 votes

Optimizing Clinical Studies Recruitment

Submitted by (@ullmann)

Improve Recruitment

If you plan to conduct randomized clinical trial, allow clusters (e. g. people who carpool, caregiver, partner, friends). You may offer (a) the same treatment to everyone in the cluster, or (b) allow alternatives (e.g. for caregivers to attend a program for ‘caregivers’). I used (a) in a small RCT with older adults, and it worked perfect. I noticed that for some populations transportation is a big issue. Thus, depending ...more »

Voting

25 votes

Optimizing Clinical Studies Recruitment

Submitted by (@mr.mac52)

Open Label Extension

I participated in an Alzheimer's disease Phase III drug trial that promised open label extension access to the study medication. The last Informed Consent form I signed stated the duration of the open label extension would run for 5 years. 90 days later the study pulled the trial drug and promised access to a reduced dosage and potential inclusion in a future trial. Now, some 14 months later the new study has been ...more »

Voting

12 votes